BCM
NTGN

Bridgeway Capital Management’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Bridgeway Capital Management’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-112,800
Closed -$133K – 1401
2019
Q4 		$133K Sell
112,800
-3,800
-3% -$6.07K ﹤0.01% 1236
2019
Q3 		$201K Sell
116,600
-42,600
-27% -$130K ﹤0.01% 1180
2019
Q2 		$755K Hold
159,200
– – 0.01% 828
2019
Q1 		$1.03M Buy
+159,200
New +$833K 0.01% 758

Other funds holding NTGN

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Athanor Capital New York $24.6M AUM 2.49% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bridgeway Capital Management's NTGN Position: Q1 2020 in Review

Bridgeway Capital Management sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q1 2020, closing a stake of 112,800 shares — an estimated $133K sold.

Bridgeway Capital Management first reported a position in NTGN in Q1 2019 and held it in 4 quarters. The position peaked at $1.03M in Q1 2019. 43 funds tracked by Wall St. Rank hold NTGN as of Q1 2020.

  • Bridgeway Capital Management reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Bridgeway Capital Management sold 112,800 Neon Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $133K.
  • Bridgeway Capital Management first reported a position in Neon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 4 quarters.
  • Bridgeway Capital Management's Neon Therapeutics, Inc. Common Stock position peaked at $1.03M in Q1 2019.
  • 43 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Bridgeway Capital Management's 13F filing for Q1 2020, filed 15 May 2020.